Journal of Oncology

Journal of Oncology / 2019 / Article

Erratum | Open Access

Volume 2019 |Article ID 7469284 | https://doi.org/10.1155/2019/7469284

Mansi A. Parasramka, Smiti Vaid Gupta, "Erratum to “Synergistic Effect of Garcinol and Curcumin on Antiproliferative and Apoptotic Activity in Pancreatic Cancer Cells”", Journal of Oncology, vol. 2019, Article ID 7469284, 2 pages, 2019. https://doi.org/10.1155/2019/7469284

Erratum to “Synergistic Effect of Garcinol and Curcumin on Antiproliferative and Apoptotic Activity in Pancreatic Cancer Cells”

Received25 Jun 2019
Accepted25 Jun 2019
Published15 Jul 2019

In the article titled “Synergistic Effect of Garcinol and Curcumin on Antiproliferative and Apoptotic Activity in Pancreatic Cancer Cells” [1], the panel in Figure showing BxPC-3 with garcinol:curcumin in a 1:4 ratio was duplicated as the panel showing Panc-1 with garcinol:curcumin in a 1:4 ratio, due to an error during the production process. The corrected Figure is shown below:

References

  1. M. A. Parasramka and S. V. Gupta, “Synergistic effect of garcinol and curcumin on antiproliferative and apoptotic activity in pancreatic cancer cells,” Journal of Oncology, vol. 2012, Article ID 709739, 8 pages, 2012. View at: Publisher Site | Google Scholar

Copyright © 2019 Mansi A. Parasramka and Smiti Vaid Gupta. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


More related articles

540 Views | 241 Downloads | 1 Citation
 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.